AM-Pharma to Participate in Upcoming Jefferies Healthcare Conference

Utrecht, The Netherlands, June 6, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Lars Boesgaard, Chief Financial Officer, is scheduled to present at the Jefferies Healthcare Conference, being held in New York, NY on Wednesday, June 8th, 2022 at 8:00 AM ET. About AM-Pharma AM-Pharma’s purpose […]

400 PATIENTS HAVE BEEN ENROLLED IN AM-PHARMA’s PIVOTAL PHASE 3 STUDY OF ILOFOTASE ALFA FOR THE TREATMENT OF SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY

Decision from the first pre-specified futility analysis at 400 patients is expected in July Utrecht, The Netherlands, April 25, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that 400 patients have now been enrolled in the main trial population in the pivotal Phase 3 REVIVAL study. […]

AM-Pharma to Participate in SVB Leerink Biopharma Private Company Connect

Utrecht, The Netherlands, March 22, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Erik van den Berg,  Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, are scheduled to participate in SVB Leerink’s Biopharma Private Company Connect on Tuesday, March 29th, 2022. The company will be […]

AM-PHARMA ANNOUNCES TWO PRESENTATIONS AT THE 27TH INTERNATIONAL CONFERENCE ON ADVANCES IN CRITICAL CARE NEPHROLOGY

The lead investigator will present an overview of AM-Pharma’s ongoing Phase 3 REVIVAL study at 11:30 AM PT (2:30 PM ET) on Thursday, March 10, 2022; and New data underscoring the correlation between acute kidney injury severity and patient outcomes following cardiac surgery will be presented in a poster session today San Diego, California and […]

AM-Pharma to Participate in Upcoming Investor and Scientific Conferences

UTRECHT, The Netherlands – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that members of its senior management team are scheduled to participate in the following investor conferences: Cowen 42nd Annual Healthcare Conference on Wednesday, March 9, 2022. The Company will be conducting investor meetings, which can be […]

AM-Pharma and Leading Experts Publish Report on State-of-the-Art Clinical Trials in Acute Kidney Injury

Utrecht, The Netherlands, January 26, 2022 – AM Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that its Chief Operating Officer, Juliane Bernholz, PhD, is among the authors of a recently published peer-reviewed article discussing the design and implementation of clinical trials for Acute Kidney Injury (AKI). With representation […]

AM-Pharma to Participate in Upcoming Investor Conferences

Utrecht, The Netherlands, January 5, 2022 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced that Erik van den Berg, the Company’s Chief Executive Officer, and Lars Boesgaard, Chief Financial Officer, will participate in the following investor conferences: Kempen’s 40th Annual Life Sciences Virtual Crossover Conference on Thursday, January […]

AM-Pharma Appoints Alexander Bastian as Vice President Value & Market Access

Utrecht, The Netherlands, 3 November, 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the appointment of Alexander Bastian as Vice President Value & Market Access, effective immediately. Mr. Bastian joins the company with over 19 years of leadership in product launch and market access strategies from […]

AM-Pharma Appoints Lars Boesgaard as Chief Financial Officer and Establishes U.S. Affiliate AM-Pharma Inc.

Utrecht, The Netherlands, 15 September, 2021 – AM-Pharma B.V., an emerging leader focused on developing therapeutics for severe medical conditions, today announced the appointment of Lars R. Boesgaard as Chief Financial Officer (CFO), effective immediately. Mr. Boesgaard’s career spans 25 years and includes CFO roles at public and private companies, where he built experience with […]

AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan

AM-Pharma to receive EUR 20 million upfront payment, and EUR 30 million related to milestones prior to regulatory submission, and up to EUR 195 million upon submission, NHI price listing and sales milestone payments bringing the overall deal value to EUR 245 million. Kyowa Kirin gains exclusive rights to develop and commercialize ilofotase alfa in […]